- Home
- IRD
as 06-20-2025 4:00pm EST
Stocks
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 62.0M | IPO Year: | N/A |
| Target Price: | $6.33 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $2.18 | Next Earning Date: | 08-15-2025 |
| Revenue: | $13,651,000 | Revenue Growth: | -28.19% |
| Revenue Growth (this year): | 51.41% | Revenue Growth (next year): | 68.84% |
Latest OPUS GENETICS INC News
IRD Breaking Stock News: Dive into IRD Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 days ago
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
Simply Wall St.
a month ago
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Simply Wall St.
a month ago
Opus Genetics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
a month ago
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
GlobeNewswire
a month ago
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
GlobeNewswire
2 months ago
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
GlobeNewswire
2 months ago
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
GlobeNewswire
2 months ago
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath
Compare IRD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRD OPUS GENETICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.